Zobrazeno 1 - 10
of 1 263
pro vyhledávání: '"F. Smit"'
Autor:
F. Benz, L. Grolig, S. Hannibal, C. Buntrock, P. Cuijpers, K. Domschke, D. D. Ebert, J. Ell, M. Janneck, C. Jenkner, A. F. Johann, A. Josef, M. Kaufmann, A. Koß, T. Mallwitz, H. Mergan, C. M. Morin, D. Riemann, H. Riper, S. R. Schmid, F. Smit, L. Spille, L. Steinmetz, E. J. W. Van Someren, K. Spiegelhalder, D. Lehr
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-17 (2024)
Abstract Background Insomnia is a highly prevalent disorder associated with numerous adverse health outcomes. Cognitive behavioural therapy for insomnia (CBT-I) is recommended as first-line treatment by clinical guidelines but is accessible to only a
Externí odkaz:
https://doaj.org/article/13736233927b4f3d98ad1be2091300e9
Autor:
Scott N. Gettinger, MD, Rudolf M. Huber, MD, PhD, Dong-Wan Kim, MD, PhD, Lyudmila Bazhenova, MD, Karin Holmskov Hansen, MD, Marcello Tiseo, MD, Corey J. Langer, MD, FACP, Luis G. Paz-Ares Rodríguez, MD, PhD, Howard L. West, MD, Karen L. Reckamp, MD, MS, Glen J. Weiss, MD, Egbert F. Smit, MD, PhD, Maximilian J. Hochmair, MD, Sang-We Kim, MD, PhD, Myung-Ju Ahn, MD, PhD, Edward S. Kim, MD, FACP, Harry J.M. Groen, MD, PhD, Joanna Pye, MS, Yuyin Liu, PhD, Pingkuan Zhang, MD, Florin Vranceanu, MD, PhD, D. Ross Camidge, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100385- (2022)
Introduction: We report brigatinib long-term efficacy and safety from phase 1/2 and phase 2 (ALTA) trials in ALK–rearrangement positive (ALK+) NSCLC. Methods: The phase 1/2 study evaluated brigatinib 30 to 300 mg/d in patients with advanced maligna
Externí odkaz:
https://doaj.org/article/78d40f5a880944a8b24323de142222e5
Autor:
Sophie M. Ernst, Joanne M. Mankor, Job van Riet, Jan H. von der Thüsen, Hendrikus J. Dubbink, Joachim G.J.V. Aerts, Adrianus J. de Langen, Egbert F. Smit, Anne-Marie C. Dingemans, Kim Monkhorst
Publikováno v:
Journal of Thoracic Oncology, 18(4), 487-498. International Association for the Study of Lung Cancer
Introduction: Patient-reported smoking history is frequently used as a stratification factor in NSCLC-directed clinical research. Nevertheless, this classification does not fully reflect the mutational processes in a tumor. Next-generation sequencing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00cf9743a1479a3c4eba3c64ec721d08
http://www.scopus.com/inward/record.url?scp=85146015148&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85146015148&partnerID=8YFLogxK
Autor:
Tomohide Tamura, Kazumasa Noda, Shinzoh Kudoh, José Baselga, Johan Vansteenkiste, Giuseppe Giaccone, Seiji Yano, Takeshi Horai, Kazuhiko Nakagawa, Ichiro Takata, Rui Ping Dong, Masahiro Fukuoka, Egbert F. Smit, Jean-Yves Douillard, Danny Rischin, Richard Eek, A. Feyereislova, Steven D. Averbuch, Yutaka Nishiwaki, Angela Macleod
Publikováno v:
Journal of Clinical Oncology. 41:1162-1171
PURPOSE To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non–small-cell lung
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45ccc160e40821bcd68e21184b9491e2
https://doi.org/10.1200/jco.22.02499
https://doi.org/10.1200/jco.22.02499
Autor:
Ard van Veelen, Judith Gulikers, Lizza E.L. Hendriks, Safiye Dursun, Juanita Ippel, Egbert F. Smit, Anne-Marie C. Dingemans, Robin van Geel, Sander Croes
Publikováno v:
van Veelen, A, Gulikers, J, Hendriks, L E L, Dursun, S, Ippel, J, Smit, E F, Dingemans, A-M C, van Geel, R & Croes, S 2022, ' Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer : The OSIBOOST trial ', Lung Cancer, vol. 171, pp. 97-102 . https://doi.org/10.1016/j.lungcan.2022.07.012
Lung Cancer, 171, 97-102. Elsevier Ireland Ltd
Lung Cancer, 171, 97-102. Elsevier Ireland Ltd
Introduction: Exposure to osimertinib, a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for treatment of non-small cell lung cancer (NSCLC) and a sensitizing EGFR mutation, can be substantially below average.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e90c1d695c2e87afae94bff515d7d9b5
http://www.scopus.com/inward/record.url?scp=85135538552&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85135538552&partnerID=8YFLogxK
Autor:
G.D. Marijn Veerman, Rene J. Boosman, Merel Jebbink, Esther Oomen-de Hoop, Anthonie J. van der Wekken, Idris Bahce, Lizza E.L. Hendriks, Sander Croes, Christi M.J. Steendam, Evert de Jonge, Stijn L.W. Koolen, Neeltje Steeghs, Ron H.N. van Schaik, Egbert F. Smit, Anne-Marie C. Dingemans, Alwin D.R. Huitema, Ron H.J. Mathijssen
Publikováno v:
EClinicalMedicine, 59:101955. Lancet Publishing Group
EClinicalMedicine, 59:101955. Elsevier
Veerman, G D M, Boosman, R J, Jebbink, M, Oomen-de Hoop, E, van der Wekken, A J, Bahce, I, Hendriks, L E L, Croes, S, Steendam, C M J, de Jonge, E, Koolen, S L W, Steeghs, N, van Schaik, R H N, Smit, E F, Dingemans, A-M C, Huitema, A D R & Mathijssen, R H J 2023, ' Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer ', EClinicalMedicine, vol. 59, 101955 . https://doi.org/10.1016/j.eclinm.2023.101955
EClinicalMedicine, 59:101955. Elsevier
Veerman, G D M, Boosman, R J, Jebbink, M, Oomen-de Hoop, E, van der Wekken, A J, Bahce, I, Hendriks, L E L, Croes, S, Steendam, C M J, de Jonge, E, Koolen, S L W, Steeghs, N, van Schaik, R H N, Smit, E F, Dingemans, A-M C, Huitema, A D R & Mathijssen, R H J 2023, ' Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer ', EClinicalMedicine, vol. 59, 101955 . https://doi.org/10.1016/j.eclinm.2023.101955
Background: Central nervous system (CNS) metastases are present in approximately 40% of patients with metastatic epidermal growth factor receptor-mutated (EGFRm+) non-small cell lung cancer (NSCLC). The EGFR-tyrosine kinase inhibitor osimertinib is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d9a0a2bc22225c345fc12f4aef0a124
https://doi.org/10.1016/j.eclinm.2023.101955
https://doi.org/10.1016/j.eclinm.2023.101955
Autor:
William Pao, Vincent A. Miller, Vikram K. Chand, Yali Fu, Bushi Wang, Gregory J. Riely, D. Ross Camidge, Scott Gettinger, Leora Horn, Harry J.M. Groen, Egbert F. Smit, Yelena Y. Janjigian
Adverse events of any grade.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc2f2bb3f801ec0d538a11c2271ee8d4
https://doi.org/10.1158/2159-8290.22532278
https://doi.org/10.1158/2159-8290.22532278
Autor:
Julian Downward, Katerina Politi, Egbert F. Smit, René Bernards, Harold Varmus, Marc Ladanyi, Yixuan Gong, Almudena García-Castaño, Javier Gómez-Román, Daniëlle A.M. Heideman, Guus J. Heynen, Anna Wurtz, Zenta Walther, Scott Gettinger, Mary Ann Melnick, Rebecca E. Saunders, Ming Jiang, Patricia H. Warne, Catherine Cowell, Elza C. de Bruin
PDF file 108K, Table S4. Clinical characteristics of human lung adenocarcinoma samples
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17fc1bd0ab84567b3626be4fede6e78f
https://doi.org/10.1158/2159-8290.22529726
https://doi.org/10.1158/2159-8290.22529726
Autor:
Julian Downward, Katerina Politi, Egbert F. Smit, René Bernards, Harold Varmus, Marc Ladanyi, Yixuan Gong, Almudena García-Castaño, Javier Gómez-Román, Daniëlle A.M. Heideman, Guus J. Heynen, Anna Wurtz, Zenta Walther, Scott Gettinger, Mary Ann Melnick, Rebecca E. Saunders, Ming Jiang, Patricia H. Warne, Catherine Cowell, Elza C. de Bruin
XLSX file 2064K, Table S1. Tabulated complete data from the first genome-wide screen. Table S2. Tabulated data from the 242 siRNA pools identified in the first genome-wide screen with the Z-scores obtained in the repeat genome-wide screen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1308461c69c1695477cd20778f15b489
https://doi.org/10.1158/2159-8290.22529723.v1
https://doi.org/10.1158/2159-8290.22529723.v1
Autor:
Julian Downward, Katerina Politi, Egbert F. Smit, René Bernards, Harold Varmus, Marc Ladanyi, Yixuan Gong, Almudena García-Castaño, Javier Gómez-Román, Daniëlle A.M. Heideman, Guus J. Heynen, Anna Wurtz, Zenta Walther, Scott Gettinger, Mary Ann Melnick, Rebecca E. Saunders, Ming Jiang, Patricia H. Warne, Catherine Cowell, Elza C. de Bruin
PDF file 415K, Supplementary Figures 1-7. Figure S1, related to Figure 1. Genome-wide siRNA screen identifies determinants of resistance to erlotinib treatment. Figure S2, related to Figure 2. Reduced Nf1 expression in erlotinib-resistant EGFR-driven
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ec3ff2c4a77fe7096343582e01b356b
https://doi.org/10.1158/2159-8290.22529732.v1
https://doi.org/10.1158/2159-8290.22529732.v1